DMIIU — Drugs Made In America Acquisition II Balance Sheet
0.000.00%
Last trade - 00:00- $654.44m
- $654.12m
Annual balance sheet for Drugs Made In America Acquisition II, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2024 December 31st | |
|---|---|
| Period Length: | — |
| Source: | PROSPECTUS |
| Standards: | USG |
| Status: | Final |
| Cash | |
| Cash and Short Term Investments | 0.017 |
| Prepaid Expenses | |
| Total Current Assets | 0.06 |
| Other Long Term Assets | |
| Total Assets | 0.138 |
| Accrued Expenses | |
| Notes Payable / Short Term Debt | |
| Total Current Liabilities | 0.255 |
| Total Long Term Debt | |
| Total Debt | |
| Total Liabilities | 0.255 |
| Common Stock | |
| Additional Paid In Capital | |
| Retained Earnings (Accumulated Deficit) | |
| Total Equity | -0.117 |
| Total Liabilities & Shareholders' Equity | 0.138 |
| Total Common Shares Outstanding |